Novartis' Cosentyx keeps up the good clearance through Year 4: Study

Novartis HQ cropped

Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some long-term data in hand that could help it on that quest.

Over the weekend, the pharma giant unveiled results showing that its psoriasis star could deliver high--and long-lasting--skin clearance in moderate-to-severe psoriasis patients over four years of therapy. 68.5% of patients in the study achieved clear or almost clear skin at the Year 1 mark, and that rate holds steady, holding at 66.4% at Year 4.

And those whose skin cleared completely on Cosentyx--43.8% of patients--got to keep enjoying that status, too, with the rate staying put at 43.5% at Year 4.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Since Novartis won approval for Cosentyx in January 2015, the company hasn’t slowed down with the med. The newcomer racked up $261 million in 2015 after launching in February, and early this year, it snagged a pair of new indications--psoriatic arthritis and ankylosing spondylitis--that’ll help pad that total for this year.

Still, though, Cosentyx will be far from alone in any of those disease areas. In psoriasis, Eli Lilly launched new-age rival Taltz earlier this year, and others aren’t far behind. Valeant is currently waiting for an FDA decision after an advisory panel backed its candidate brodalumab, and Johnson & Johnson over the weekend rolled out data showing its prospect guselkumab had beaten out AbbVie inflammatory giant Humira in a head-to-head study.

And in psoriatic arthritis, Pfizer’s Xeljanz for one is gearing up to provide a challenge. Companies including J&J--which makes blockbuster Stelara--could give Novartis a run for its money in ankylosing spondylitis, too, research and consulting firm GlobalData predicted last year. 

- read Novartis' release

Related Articles:
J&J's next-gen psoriasis med tops Humira in head-to-head showdown
Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals
Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, too


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.